{
 "drug": "Tazemetostat Hydrobromide Tablet",
 "asOf": "2026-08-25",
 "status": "discontinuing",
 "since": "03/27/2026",
 "dayN": 151,
 "cat": "Oncology",
 "companies": [
  "Epizyme, Inc. (An Ipsen Company)"
 ],
 "reasons": [],
 "records": [
  {
   "discontinued_date": "03/27/2026",
   "update_type": "New",
   "initial_posting_date": "03/27/2026",
   "package_ndc": "72607-100-00",
   "generic_name": "Tazemetostat Hydrobromide Tablet",
   "contact_info": "(855)-463-5127",
   "related_info": "Discontinuation of the manufacture of the drug product",
   "openfda": {
    "application_number": [
     "NDA211723"
    ],
    "brand_name": [
     "TAZVERIK"
    ],
    "generic_name": [
     "TAZEMETOSTAT"
    ],
    "manufacturer_name": [
     "Epizyme, Inc."
    ],
    "product_ndc": [
     "72607-100"
    ],
    "product_type": [
     "HUMAN PRESCRIPTION DRUG"
    ],
    "route": [
     "ORAL"
    ],
    "substance_name": [
     "TAZEMETOSTAT HYDROBROMIDE"
    ],
    "rxcui": [
     "2274384",
     "2274390"
    ],
    "spl_id": [
     "c4bd8d8a-22c1-4911-a9b4-7368582d8e5d"
    ],
    "spl_set_id": [
     "7db07b5f-4e22-467c-9c0a-f830b08dbb1d"
    ],
    "package_ndc": [
     "72607-100-00"
    ],
    "unii": [
     "6P89T5M073"
    ]
   },
   "update_date": "03/27/2026",
   "therapeutic_category": [
    "Oncology"
   ],
   "dosage_form": "Tablet",
   "presentation": "Tazverik, Tablet, 200 mg (NDC 72607-100-00)",
   "company_name": "Epizyme, Inc. (An Ipsen Company)",
   "status": "To Be Discontinued"
  }
 ]
}